

Q2

Quarterly report

Senzime AB (publ.)

April - June 2024



QUARTERLY REPORT APRIL-JUNE 2024

CEO COMMENT

“Strong growth in the US market, we’re gaining market share and our technology is increasingly being established as the new clinical standard in operating rooms around the world”

KPI's

14,9

Million SEK
in net sales

76%

Total sales growth
vs. Q2 2023.

167%

US market sales growth
vs. Q2 2023

2 632 (1 709)

TetraGraph-Systems
delivered to market
since start¹

48 680 (25 035)

Number of TetraSens
disposable sensors sold
during the quarter.

370 (259)

Hospitals with
TetraGraph systems in
EU, USA, Japan och
South Korea.

¹ Figures in brackets are previous
year quarter

HIGHLIGHTS



Strong US market growth

Sales in the US market increased by 167% driven by recurring sensor sales and new contract wins. Deals include some of the most prestigious and top-rated hospitals in the United States.



Win of larger Veterans Affairs public tender

Senzime wins another major public procurement from Veterans Affairs Health (VA), the single largest health care provider in the United States.



First signed GPO agreement

Senzime signs its first Group Purchasing Organization (GPO) agreement in the US and becomes so-called. sole source supplier to one of the largest healthcare players in the USA.



New US study strengthens the competitiveness of Senzime's technology

Clinical study published in the leading journal Anesthesiology confirms the leading accuracy and precision of Senzime's TetraGraph system and highlights the variability in data of competing products.



Strengthened patent protection

Senzime receives new European patent for the TetraGraph system. The patent portfolio is now approaching 100 patents.

QUARTERLY REPORT APRIL–JUNE 2024

SECOND QUARTER 2024 (1 APRIL – 30 JUNE)

- Net sales amounted to TSEK 14,917 (8,462), an increase of 76 %
- Sales of disposable sensors amounted to TSEK 8,412 (4,390), an increase of 92 %
- In the USA, net sales increased to TSEK 10,973 (4,108), an increase of 167 %
- Currency-adjusted net sales increased by 76 %
- The gross margin before depreciation amounted to 63.3 % (70.0)
- Operating costs amounted to TSEK 39,770 (37,101)
- Operating profit before depreciation amounted to TSEK -29,239 (-30,201)
- The result after financial items amounted to TSEK -34,259 (-35,264)
- Earnings per share amounted to SEK -0.28 (-0.42)
- Cash and cash equivalents as of June 30th amounted to TSEK 80,184 (41,635)

SIGNIFICANT EVENTS DURING SECOND QUARTER

- Senszime secures contracts with several leading US hospitals in robotic surgery and monitoring of children undergoing anesthesia.
- Senszime wins another major public procurement from Veterans Health in the USA.
- Senszime signs its first GPO agreement in the US and becomes so-called. sole source supplier to one of the largest healthcare players in the USA.
- Clinical study published in the leading scientific journal Anesthesiology confirming the leading accuracy and precision of Senszime's EMG-based TetraGraph system.
- Senszime receives a new European patent for the TetraGraph system.
Senzzime wins contract with the most prestigious and highest-rated children's hospital in the United States.

HALF YEAR 2024 (1 JANUARY – 30 JUNE)

- Net sales amounted to TSEK 27,037 (15,750), an increase of 72 %
- Sales of disposable sensors amounted to TSEK 15,668 (8,234), an increase of 90 %
- In the USA, net sales increased to TSEK 20,011 (9,182 KSEK), an increase of 118 %
- Currency-adjusted net sales increased by 71 %
- The gross margin before depreciation amounted to 63.7 % (69.3)
- Operating costs amounted to TSEK 72,576 (69,479)
- Operating profit before depreciation amounted to TSEK -53,150 (-56,661)
- The result after financial items amounted to TSEK -62,978 (-66,955)
- Earnings per share amounted to SEK -0.51 (-0.84)
- Cash and cash equivalents as of June 30th amounted to TSEK 80,184 (41,635)

SIGNIFICANT EVENTS DURING FIRST HALF YEAR

- Expansion of the commercial sales organization in the US, a Vice President Global Marketing is added, and the US headquarters is moved from Boston to St. Louis.
- Senszime's licensee Fukuda Denshi launches the first integrated TetraGraph module on the Japanese market.
- Senszime secures its largest US deal to date from leading Houston-based university hospital system with deliveries of more than 300 TetraGraph systems.
- Senszime secures contracts with several leading US hospitals in robotic surgery and monitoring of children undergoing anesthesia.
- Senszime wins another major public procurement from Veterans Health in the USA.
- Senszime signs its first GPO agreement in the USA and becomes the sole source supplier to one of the largest healthcare players in the USA..


EVENTS AFTER THE END OF THE SECOND QUARTER

- Senszime signs new contract with a top-10 ranked health care system (IDN) in the southeastern United States that expands use of the TetraGraph system and is expected to quadruple.
- Senszime provides market update and outlines higher growth ambitions


KPI's SECOND QUARTER 2024

TSEK	Q2		HALF YEAR		TOT YEAR
	2024	2023	2024	2023	2023
Net Sales	14,917	8,462	27,037	15,750	35,754
EBITDA	-29,239	-30,201	-53,150	-56,661	-116,793
Profit (loss) after financial items	-34,259	-35,264	-62,978	-66,955	-137,159
Earnings per share (SEK)	-0.28	-0.42	-0.51	-0.84	-1.45
Gross margin excl. amortization (%)	63.3	70.0	63.7	69.3	69.8
Solidity (%)	81.3	82.9	81.3	82.9	86.7
Sales Growth (%)	76.3	148.6	71,7	173,2	154,8


Net Sales Q2 (MSEK)




Net Sales Total R 12 month TSEK



Net Sales Disposables R 12 month TSEK



Total delivered base of TetraGraph-systems¹




Comment: (1) Refers to all accumulated deliveries of TetraGraph monitors to end customers, distributors and partners. Some of the delivered base are still in stock at sales partners or has not yet been installed in a hospital environment

SALES OVERVIEW


TSEK Q2 Apr-Jun	Reported			Currency adjusted
	2024	2023	Growth	Growth
US	10,973	4,108	167%	163%
Devices/other	5,189	1,160	347%	341%
Disposables	5,784	2,948	96%	93%
Europe	2,167	2,216	-2%	-2%
Devices/other	549	1,175	-53%	-53%
Disposables	1,618	1,041	55%	54%
RoW	1,778	2,138	-17%	-16%
Devices/other	767	1,737	-56%	-54%
Disposables	1,011	401	152%	149%
Total Q2	14,917	8,462	76%	76%
Devices/other	6,505	4,072	60%	61%
Disposables	8,412	4,390	92%	89%

TSEK H1 Jan-Jun	Reported			Currency adjusted
	2024	2023	Growth	Growth
US	20,011	9,183	118%	116%
Devices/other	8,959	3,368	166%	163%
Disposables	11,051	5,815	90%	89%
Europe	3,613	4,364	-17%	-18%
Devices/other	996	2,399	-58%	-58%
Disposables	2,617	1,965	33%	31%
RoW	3,413	2,203	55%	59%
Devices/other	1,413	1,749	-19%	-16%
Disposables	2,000	454	341%	341%
Total H1	27,037	15,750	72%	71%
Devices/other	11,369	7,515	51%	52%
Disposables	15,668	8,234	90%	89%


Net Sales by product group (Q2)



Net Sales by region (Q2)



Accumulated number of disposable sensors sold





This is Senzime.

- 1. Senzime is a global medical technology company** that develops algorithm-based patient monitoring systems with the goal of eliminating the risk of complications for over 100 million patients every year.
- 2. Our systems enable precision-based monitoring** of patients during and after surgery. It is about ensuring the correct individual dose of anesthesia-related drugs, indicating when it is safe to breathe on your own again and identifying early post-operative complications.
- 3. Our foundation is based on extensive research and** collaborations with leading academic institutions such as Mayo Clinic, Harvard, and Massachusetts General Hospital. Our systems meet the requirements of new clinical guidelines in the US, Europe, and many other countries.
- 4. We have a commercial operations covering over 30 markets** with subsidiaries in the US and Germany, as well as several licensing and distribution partnerships in other regions.
- 5. ...and we are one of the fastest growing** medical technology companies on the Nasdaq Main Market Stockholm with long-term institutional owners and a world-class team.

CEO COMMENT

Strong growth in the US market, we are gaining market shares, and our technology is increasingly being established as the new clinical standard in operating rooms around the world

It has been another eventful quarter for Senzime. We continue to report strong growth and net sales increased by 76 percent vs Q2 2023 to SEK 14.9 million. Last year's second quarter included a one-off licensing revenue and excluding that, the sales increase was over 100 percent. This was again another quarter with record sales.

Our US revenue continues to develop strongly with an increase of 167 percent vs Q2 2023 Strategically important new hospital contracts and recurring sales of disposable sensors to the installed base of TetraGraph systems contributed to the growth. The expanded sales organization in the US is proving to be very successful. The utilization rate of systems continues to increase, and we delivered almost twice as many disposable sensors as the previous year.

During the quarter, we secured a total of over 40 new hospital contracts. Many of these contracts are based on extensive competitive clinical evaluations that we have won. We have not lost any clinical evaluation during the quarter to a competitor. I also note the trend in the US with an increased proportion of contracts that we win without needs of evaluations, leading to significantly faster sales processes.

Among the deals we secured during the quarter, it's worth mentioning the tender win from Veterans Affairs, the single largest healthcare provider in the US, contract with the most prestigious and highest-ranked children's hospital in the US, as well as deliveries to robotic surgery rooms within the highest-ranked hospital system in the US.

We signed our first GPO agreement in the USA as sole supplier to one of the largest healthcare players in the US. The procurement agreement validates the hospital market's increased demand for our products, and hospitals within the group can now purchase without the need for further clinical evaluation. The first deals within the agreement came in after the end of the quarter. The GPO agreement is a major victory for our unique technology and our delivery capabilities.

Businesses in Japan and South Korea are also showing good growth. Our Japanese license partner Fukuda Denshi reports success in sales of its integrated module with "TetraGraph inside" launched in the first quarter of this year. The module is the first of its kind powered by our algorithms and sensors and launched as an accessory to Fukuda's extensive installed base of patient monitors. The healthcare strike in South Korea has continued, but despite this we have been able to once again deliver products to the market.

The European market is slow in the conversion from AMG to EMG-based monitoring. We often enter the hospitals by supplying operating rooms that run robotic surgery and high demands on close monitoring. We then methodically convert room by room. Europe differs from the US market in that AMG-based monitoring has a stronger foothold since the 1990s, which leads to somewhat slower technology change. Further clinical guidelines have been announced in Europe for 2025 and I am confident that the European market will also start to change

Our technology is increasingly becoming established as the new clinical standard. During the quarter, another important US study was published that validated our technology and highlighted the weaknesses and patient risks of conventional AMG technology. The study comparing our EMG technology with AMG published in the high impact *Anesthesiology* confirms the leading accuracy and precision of our TetraGraph system.

Our gross margin was slightly affected by the rapid growth in the US with a high proportion of instrument sales during the quarter. These systems will eventually generate recurring sales of higher-margin sensors. Last year's Q2 gross margin was positively impacted by a one-time license fee. We're also continuously investing in the scale-up of our production and during the quarter we moved into new efficient and sustainable premises in Uppsala to meet our long-term growth needs.

Our operating costs were slightly higher mainly due to non-recurring effects

related to our relocation in Uppsala and market launch of new products. We also continue to drive intense innovation work to secure our long-term leading position in the technology shift that is taking place in the market.

The new American and European clinical guidelines published at the beginning of 2023 are catalysts for our business. Over 200 million patients undergo major surgical procedures each year, of which approximately half receive muscle paralyzing drugs as part of anesthesia. These 100 million patients are our target market, and we focus on selling our technology to the approximately 160,000 operating rooms located in the US, Europe, Japan and South Korea. The conversion is partly from AMG-based monitoring solutions that dominate the European market, and partly from manual, subjective monitoring methods that dominate in the USA.

In conjunction with this report, we announced a market update and an outline of our future high growth ambitions. The update is the result of a rapidly expanding addressable market, the new supportive EU and US clinical guidelines, and strong clinical adoption of EMG-based neuromuscular monitoring technology in predominately US, Japan and South Korea.

In summary, our mission is to be the undisputed global market leader in the field of EMG-based quantitative neuromuscular monitoring. Our longer 5–7 year growth ambitions are to reach revenues exceeding SEK 1 billion. The shorter-term guidance is to reach revenues of 250–350 MSEK and be cash flow positive during 2026.

The shorter guidance is a 12-month extension of previously communicated targets in 2022. We are surpassing our revenue targets in the US, Japan, and South Korea, but the European market transition to EMG is still advancing significantly slower than expected. Yet at the same time, we're increasing our longer-term ambitions for the company.

The focus and direction of Senzime is crystal clear – we are building the

undisputed market leader in the digital and clinical shift that is now taking place in operating rooms worldwide. The commercial breakthrough for Senzime is a fact. We shall achieve profitability through high market penetration, high utilization rate of our systems, offer the most user-friendly and innovative solutions and scale up with the support of smart, industrial partnerships. Everything is made possible by our brilliant team.

Our pipeline is strong, we are gaining market share, and we note higher demand in

the market. Q3 has started strong and if I include sales through July, we are at a three-digit growth rate on a rolling-12 basis, compared to the same seven-month period last year. The outlook for the full year looks very positive, and I can promise exciting things will be announced during the autumn.

Uppsala, Aug 26, 2024

Philip Siberg, CEO



Comments to the report

Revenue and profit in the second quarter 2024

The group's net sales for the second quarter of 2024 amounted to TSEK 14,917 (8,462), corresponding to an increase of 76 percent compared to the same quarter of the previous year. Adjusted for currency changes, sales increased by 76 percent. The growth was primarily driven by increased sales of TetraGraph systems and disposable sensors in the US market and in Asia. For disposable sensors, the US accounts for a 96 percent increase, Europe for a 55 percent increase, and Asia for a 206 percent increase, mainly in Japan and South Korea.

Sales of monitors and accessories increased by 60 percent driven by a number of business wins in the US as well as new deliveries of monitors to our license partner Fukuda in Japan. Sales of disposable sensors increased by 89 percent adjusted for currency changes. In the US, total underlying sales adjusted for currency effects, increased by 163 percent. In the main markets, it was primarily the installed base of monitors that drove sensor sales growth.

The gross margin before depreciation during the second quarter amounted to 63.3 percent, compared to 70.0 percent for the corresponding quarter last year. A decrease is attributable to product and customer mix as well as temporary one-off adjustments to older consumables. The US market is affected by some price pressure on instruments, which has negatively affected the margin compared to the same period last year. We see certain material price increases in our production which we continuously work to balance out with adjusted prices to our customers. We carry out extensive innovation work that aims to continuously launch products that strengthen the gross margin in the long term to levels above 70 percent.

During the second quarter, the group's total operating expenses amounted to TSEK 39,770 (37,101). Direct operating expenses amounted to TSEK 39,574 (41,054) and other operating income and operating expenses, attributable to currency-related recalculations of balance sheet items, amounted to TSEK 196 (-3,953).

The operating profit during the second quarter amounted to TSEK -34,720 compared with TSEK -35,257 in the corresponding quarter of the previous year. Profit after financial items amounted to TSEK -34,259 to be compared with TSEK -35,264 in the corresponding period last year. The loss also decreased in this subperiod, this time by just over SEK 1.0 million compared to the same period last year.

Revenue and profit January – June 2023

The group's net sales for the period January - June 2024 amounted to TSEK 27,037 (15,750), corresponding to an increase of 72 percent compared to the same period last year. Adjusted for currency changes, sales increased by 71 percent, a marginal currency impact as no major currency changes have occurred compared to the corresponding period last year.

The growth was primarily driven by increased sales in the US and Asia. In the US, total underlying sales adjusted for currency effects, increased by 116 percent and Asia grew by 66 percent, adjusted for currency effects. Adjusted for one-off licensing revenue for ExSpirom in China last year, Asia total sales grew 240 percent. In Europe, we are currently seeing negative growth compared to the same period last year, driven by longer sales processes for capital goods. However, sensor sales in Europe increase by 31 percent. On the US market, sensor sales increased by 89 percent and in Asia by 443 percent.

Sales of monitors and accessories increased by 51 percent driven by several new business wins in the US as well as new deliveries of monitors to our license partner Fukuda in Japan. Total sales of disposable sensors increased by 89 percent adjusted for currency changes.

The gross margin before depreciation for the first half of 2024 amounted to 63.7 percent, compared to 69.3 percent for the same period last year. A decrease is attributable to product and customer mix as well as temporary one-off adjustments to older consumables. We have also seen price pressure in the US market on capital equipment, which has a temporary negative impact on the margin.

During the first half of 2024, the group's total operating expenses amounted to TSEK 72,576 (69,479). Direct operating expenses amounted to TSEK 76,910 (72,913) and other operating income and operating expenses, attributable to currency-related recalculations of balance sheet items, amounted to TSEK -4,334 (-3,434). The increase in direct operating costs is mostly attributable to building up the US commercial organization with, among other things, investment in the US Marketing VP position and further investments to strengthen the US sales and clinical teams in the USA.

The operating profit during the first half of 2024 amounted to TSEK -64,055 compared with TSEK -66,680 during same period last year. Profit after financial items amounted to TSEK -62,978 to be compared with TSEK -66,955 in the same period last year. The loss decreased for the second quarter in a row and, in total for the period, the loss decreased by approximately SEK 4 million compared to the same period last year.

Cash-flow and Investments

The cash flow from current operations, including changes in working capital, amounted to TSEK -30,884 (-27,972) for the second quarter. The negative cash flow is mostly due to the negative result and negative change in working capital, mostly attributable to increased inventory to ensure increased production and demand for our products as well as an increase in accounts receivable related to increased sales.

The cash flow from investment activities for the first quarter amounted to TSEK -4,685 (-2,298). Investments during the period are largely related to the activation of development projects. The cash flow from financing activities amounted to TSEK -1,057 (-1,100) for the second quarter and is mostly related to payments relating to leasing costs.

The cash flow from current operations including changes in working capital for the period January - June 2024 amounted to TSEK -60,299 KSEK (-61,206). The negative cash flow is mostly due to the negative result and negative change in working capital which is mostly reflected in the increase in accounts receivable due to increased sales as well as increased inventory to ensure increased production and demand for our products.

The cash flow from investment activities for the period January - June 2024 amounted to TSEK -8,274 SEK (-4,343) and is largely related to the activation of development projects. The cash flow from financing activities for the period January - June 2024 amounted to TSEK -2,366 SEK (81,002) and is mostly related to payments relating to leasing costs. Last year's positive cash flow from financing activities is related to a rights issue that Senszime carried out in March 2023, which brought to the company approximately 83 million SEK after issue and guarantee costs.

Financial position

Senzime shows strong sales growth combined with a stable cost level. At the end of the period, the company's cash and cash equivalents amounted to TSEK 80,184 (41,635), the group's equity to TSEK 319,693 (283,912) and the equity ratio 81.3 percent (82.9).

The board works continuously to secure the company's long-term financing to ensure the operation of the business assuming investments and ventures. The company's growth plan is continuously balanced against the financial resources that are available at any given time. The board has a positive view of being able to raise capital or provide other types of funding that are beneficial to the company.

Stock options

At the time of publication of this interim report, the group has three employee option programs with a total of 2,330,000 options, of which 214,000 options have expired. See note 10 for detailed descriptions. Based on the existing number of shares and outstanding employee stock options and warrants, the dilution, if all outstanding options and warrants are exercised for new shares, is calculated to amount to a maximum of 2.05 percent. The corresponding figure excluding hedge options amounts to 1.74 percent.

At the annual general meeting in May 2024, it was decided on another employee option program with a total of 1,200,000 options and allocation will take place during the third quarter of 2024.

Parent company and subsidiaries

The majority of the group's operations are conducted in the parent company. For comments on the parent company's results, refer to the comments submitted for the group. The American company Respiratory Motion Inc. was acquired in the third quarter of 2022 and is a 100 percent wholly owned subsidiary of Senszime AB (publ.). The US subsidiary Senszime Inc. started its operational activities in the second quarter of 2020. Sales in the US are carried out under its own auspices. In the first quarter of 2021, the German subsidiary Senszime GmbH started its operations. The group's two other subsidiaries only hold certain rights which have been licensed to the parent company against payment in the form of royalties.

Sustainability

Senzime's operations contribute to improved global health and patient safety by reducing anesthesia and breathing-related complications and lowering healthcare costs in connection with surgical procedures and emergency treatments. Senzime's sustainability work supports the commitment to patients and strives for sustainable development based on responsible action and in line with the fundamental values.

In 2023, Senzime signed an agreement with the UN Global Compact, which means that the company commits to operating according to their 10 principles, which include labor law, human rights, anti-corruption and the environment. In 2024, the company's ISO 14001 environmental management system was recertified.

Other significant events in the quarter

The dialogue between Senzime's US subsidiary Senzime Inc. and Florida-based Mercury Medical related to a terminated distribution agreement in 2022 has been put on hold.

Significant events after the end of the quarter

Senzime announced that the company signed a new contract with a top 10 ranked Integrated Delivery Network (IDN) healthcare system in the southeastern United States. The contract expands the use of the TetraGraph system from currently only being used on children to now being used on all patients receiving muscle relaxant drugs as part of anesthesia. Annual volumes of disposable sensors are expected to quadruple, and the healthcare system is expanding to have 75 TetraGraph systems installed in operating rooms to safely monitor adults and children.

Senzime announced market update and outlined growth ambitions with goal to be the undisputed global market leader in the field of EMG-based quantitative neuromuscular monitoring, longer-term growth ambitions are to reach revenues exceeding SEK 1 billion, and shorter-term guidance to reach revenues of 250-350 MSEK and be cash flow positive during 2026.

Risks and uncertainty factors

Several risk factors can have a negative impact on the operations of Senzime. It is therefore of great importance to consider relevant risks alongside the company's growth opportunities. An account of the group's significant financial and business risks can be found in the management report and in the annual report for 2023. No further significant risks are deemed to have arisen.

Covid-19 and the geopolitical situation

Like many other companies, Senzime has faced major challenges as a consequence of the Covid-19 pandemic. The basic need for neuromuscular monitoring has not diminished, although operations during the pandemic have been postponed accommodating and allow for the availability of medical personnel. The pandemic mainly affected the number of new trials and sales in the years 2020 and 2021. Access to the hospitals has varied between different countries. However, Senzime has seen increased access to the hospitals since 2022 and full access again since 2023. Senzime has no operations in Russia, Ukraine, Israel or Palestine.

Review

This interim report has not been subject to review by the company's auditors.

Board of Directors' certification

The Board of Directors and CEO certify that this interim report gives a true and fair view of the parent company's and the group's operations, financial position, and results of operations, and reviews the significant risks and uncertainties faced by the parent company and companies in the group.

Uppsala August 26, 2024

Per Wold-Olsen

Chairman of the Board

Adam Dahlberg

Vice Chairman of the Board

Sorin Brull

Board member

Göran Brorsson

Board member

Eva Walde

Board member

Lars Axelson

Board member

Philip Siberg

Chief Executive Officer

Condensed Consolidated Statement of Comprehensive Income

Amounts in SEK thousands	Note	Q2		Jan-Jun		Full-year
		2024	2023	2024	2023	2023
Net sales	2	14,917	8,462	27,037	15,750	35,754
Cost of goods sold	3	-9,867	-6,618	-18,515	-12,951	-27,415
Gross profit (loss)		5,050	1,844	8,522	2,799	8,339
Development expenditure	4	-5,577	-5,358	-12,026	-10,303	-19,363
Selling expenses	4	-24,023	-21,397	-46,210	-36,998	-77,682
Administrative expenses	4 & 5	-9,974	-14,299	-18,674	-25,612	-45,107
Other operating income		7,304	5,610	14,891	6,466	15,290
Other operating expenses		-7,500	-1,657	-10,557	-3,032	-18,837
Earnings before interest and taxes		-34,720	-35,257	-64,055	-66,680	-137,360
Financial income		683	179	1,463	179	999
Financial expenses		-222	-186	-387	-454	-798
Financial items - net		461	-7	1,076	-275	201
Profit (loss) after financial items		-34,259	-35,264	-62,978	-66,955	-137,159
Income tax		848	900	1,638	1,788	3,010
Profit (-loss) for the period		-33,411	-34,364	-61,340	-65,167	-134,149

Condensed Consolidated Statement of Comprehensive Income

Amounts in SEK thousands	Note	Q2		Jan-Jun		Full-year
		2024	2023	2024	2023	2023
Profit (-loss) for the period		-33,411	-34,364	-61,340	-65,167	-134,149
Other comprehensive income						
Items reclassifiable to profit or loss						
Translation differences		-113	4,795	5,344	3,983	-3,325
Total comprehensive income		-33,524	-29,569	-55,996	-61,184	-137,474

The year's profit and total comprehensive income is attributable in its entirety to the parent company's shareholders.

Earnings per share, calculated on the period's earnings attributable to the parent company's shareholders.

SEK	Note	Q2		Jan-Jun		Full-year
		2024	2023	2024	2023	2023
Weighted average number of shares, before dilution	6	119,705,523	82,566,660	119,705,523	77,634,509	92,269,497
Weighted average number of shares, after dilution	6	119,705,523	82,566,660	119,705,523	77,634,509	92,269,497
Earnings per share, basic and diluted, SEK	6	-0.28	-0.42	-0.51	-0.84	-1.45

Condensed Consolidated Balance Sheet

Assets

Amounts in SEK thousands	June 30		December 31
	2024	2023	2023
ASSETS			
Non-current assets			
Intangible assets	234,425	246,036	227,193
Property plant and equipment	3,525	2,788	2,592
Rights of use	24,289	13,019	11,931
Other financial assets	4,569	4,015	4,431
Total non-current assets	266,808	265,858	246,147
Current assets			
Inventories	25,634	20,251	20,340
Trade receivables and other receivables	13,463	7,961	8,569
Other receivables	3,363	4,892	4,819
Prepaid expenses and accrued income	3,749	2,041	2,238
Cash and cash equivalents	80,184	41,635	151,009
Total current assets	126,393	76,780	186,975
TOTAL ASSETS	393,201	342,638	433,122

Condensed Consolidated Balance Sheet

Equity and Liabilities

Amounts in SEK thousands	June 30		December 31
	2024	2023	2023
EQUITY AND LIABILITIES			
Equity	319,693	283,912	375,477
LIABILITIES			
Non-current liabilities			
Provisions	3,849	3,280	3,750
Lease liability	20,828	9,905	8,578
Deferred tax liability	20,951	24,206	21,767
Total non-current liabilities	45,628	37,391	34,095
Current liabilities			
Lease liability	3,242	2,569	2,890
Trade payables	7,775	3,711	5,146
Other current liabilities	3,467	3,092	3,608
Accrued expenses	13,396	11,963	11,906
Total current liabilities	27,880	21,335	23,550
TOTAL EQUITY AND LIABILITIES	393,201	342,638	433,122

Condensed Consolidated Statement of Change in Equity

Attributable to parent company's shareholders

Amounts in SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings incl. profit (loss)	
				for the year	Total equity
Adjusted opening balance as of 1 January 2023	8,735	636,729	4,302	-387,863	261,903
Profit (-loss) for the period				-65,167	-65,167
Other comprehensive income			3,983		3,983
Total comprehensive income	-	-	3,983	-65,167	-61,184
Transactions with shareholders in their capacity as owners					
Employee stock options				350	350
New share issue	1,585	90,364			91,949
Expenses attributable to new share issues		-9,106			-9,106
Total transactions with shareholders	1,585	81,258	-	350	83,193
Closing equity June 30 2023	10,320	717,987	8,285	-452,680	283,912

Attributable to parent company's shareholders

Amounts in SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings incl. profit (loss)	
				for the year	Total equity
Opening balance as of January 1, 2024	14,963	880,690	977	-521,153	375,477
Profit (-loss) for the period				-61,340	-61,340
Other comprehensive income			5,344		5,344
Total comprehensive income	-	-	5,344	-61,340	-55,996
Transactions with shareholders in their capacity as owners					
Employee stock options				548	548
Expenses attributable to new share issues		-336			-336
Total transactions with shareholders	-	-336	-	548	212
Closing equity June 30 2024	14,963	880,354	6,321	-581,945	319,693

Condensed Consolidated Statement of Cash Flow

Amounts in SEK thousands	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Cash flow from operating activities					
Earnings before interest and taxes	-34,719	-35,257	-64,054	-66,680	-137,360
<i>Adjustment for non-cash items</i>					
Depreciation and amortization	5,480	5,056	10,904	10,018	20,567
Other non-cash items	1,194	240	-4,495	339	1,049
Interest paid	-67	-6	-67	-92	-92
Interest received	111	-	111	-	999
Income tax paid	32	-698	-294	-811	-331
Cash flow from operating activities before change in working capital	-27,969	-30,665	-57,895	-57,226	-115,168
Cash flow from change in working capital					
Increase/decrease in inventories	-3,610	1,925	-4,845	1,401	1,312
Increase/decrease in trade receivables	-4,878	-2,565	-4,460	-3,751	-4,359
Increase/decrease in operating receivables	583	-301	1,401	-466	-590
Increase/decrease in trade payables	2,777	-396	4,070	-3,607	-2,172
Increase/decrease in operating payables	2,213	4,030	1,430	2,443	7,069
Total change in working capital	-2,915	2,693	-2,404	-3,980	1,260
Cash flow from operating activities	-30,884	-27,972	-60,299	-61,206	-113,908
Cash flow from investing activities					
Investments in tangible assets	-1,198	-683	-1,734	-738	-950
Investments in intangible assets	-3,487	-1,615	-6,540	-3,605	-6,871
Cash flow from (-used in) investing activities	-4,685	-2,298	-8,274	-4,343	-7,821
Cash flow from financing activities					
Payments made for repayment of lease liabilities	-1,057	-933	-2,030	-1,841	-3,678
New share issue, net of transaction expenses	-	-167	-336	82,843	250,189
Cash flow from financing activities	-1,057	-1,100	-2,366	81,002	246,511
Decrease/increase in cash and cash equivalents	-36,626	-31,370	-70,939	15,453	124,782
Cash and cash equivalents at beginning of period	116,856	73,803	151,009	26,035	26,035
Exchange difference in cash and cash equivalents	-46	-798	114	147	192
Cash and cash equivalents at end of period	80,184	41,635	80,184	41,635	151,009

Parent company Income Statement

Amounts in SEK thousands	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Net sales	16,450	12,845	30,425	20,319	38,919
Cost of goods sold	-7,445	-6,004	-13,952	-9,827	-18,220
Gross profit (loss)	9,005	6,841	16,473	10,492	20,699
Development expenditure	-3,944	-3,519	-8,382	-6,943	-13,199
Selling expenses	-26,049	-15,441	-48,826	-18,767	-72,408
Administrative expenses	-9,872	-12,694	-17,990	-22,725	-39,837
Other operating income	6,701	5,629	14,237	6,486	15,298
Other operating expenses	-7,021	-1,313	-9,253	-2,673	-18,557
Earnings before interest and taxes	-31,180	-20,497	-53,741	-34,130	-108,004
Financial income	2,735	2,089	5,508	3,037	7,328
Financial expenses	-19	-6	-19	-28	-120,125
Financial items - net	2,716	2,083	5,489	3,009	-112,797
Profit (loss) after financial items	-28,464	-18,414	-48,252	-31,121	-220,801
Profit (-loss) for the period	-28,464	-18,414	-48,252	-31,121	-220,801

In the parent company, there are no items reported as other comprehensive income, which is why total comprehensive income corresponds to the period's result.

Parent Company Balance Sheet

Assets

Amounts in SEK thousands	June 30		December 31
	2024	2023	2023
ASSETS			
Non-current assets			
Intangible fixed assets	31,476	23,553	25,854
Property plant and equipment	2,741	1,340	1,416
Financial assets	156,269	260,754	137,139
Total non-current assets	190,486	285,647	164,409
Current assets			
Inventories	21,475	14,731	17,381
Trade receivables and other receivables	6,141	7,589	5,367
Receivables from Group companies	9,428	4,674	8,606
Prepaid expenses and accrued income	3,777	1,889	2,345
Cash and bank balances	76,686	38,568	147,853
Total current assets	117,507	67,451	181,552
TOTAL ASSETS	307,993	353,098	345,961

Parent Company Balance Sheet

Equity and Liabilities

Amounts in SEK thousands	June 30		December 31
	2024	2023	2023
EQUITY AND LIABILITIES			
Equity			
Restricted equity	49,712	37,825	43,986
Non-restricted equity	200,091	281,954	253,858
Total equity	249,803	319,779	297,844
LIABILITIES			
Non-current liabilities			
Provisions	3,849	3,280	3,750
Total non-current liabilities	3,849	3,280	3,750
Current liabilities			
Trade payables	6,894	2,776	4,658
Liabilities to Group companies	34,987	14,516	28,685
Other current liabilities	1,848	2,114	2,490
Accrued expenses	10,612	10,633	8,534
Total current liabilities	54,341	30,039	44,367
TOTAL EQUITY AND LIABILITIES	307,993	353,098	345,961

Notes on the consolidated accounts

Not 1. Accounting policies

This interim report and summary for the second quarter ended June 30th, 2024 has been prepared in accordance with the international accounting standard IAS 34 "Interim reporting". The term "IFRS" in this document includes the application of IAS and IFRS, as well as interpretations of these recommendations published by the IASB's Standards Interpretation Committee (SIC) and IFRS Interpretation Committee (IFRIC)

The application of the accounting principles is in accordance with those contained in the Annual Report for the financial year ended 31 December 2023 and should be read together with this interim report. There are no changes to IFRS in 2024 that are estimated to have a significant impact on the results and financial position of the group. Unless otherwise specifically stated, all amounts are reported in thousands of kronor (TSEK). Information in parentheses refers to the comparison year.

Not 2. Division of net Sales

Amounts in SEK thousands	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Devices/Other	6,505	4,072	11,369	7,515	16,228
- <i>there of royalties</i>	141	1,199	265	1,201	1,336
Disposables	8,412	4,390	15,668	8,234	19,526
Total	14,917	8,462	27,037	15,750	35,754

Not 3. Costs of goods sold

Amounts in SEK thousands	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Cost of materials	4,342	1,975	7,799	3,812	8,450
Personnel expenses	448	279	822	428	1,030
External services	623	206	1,031	456	1,032
Depreciation and amortization	4,454	4,158	8,863	8,255	16,903
Total	9,867	6,618	18,515	12,951	27,415

Not 4. Development, selling and administrative expenses by nature of cost

Amounts in SEK thousands	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Personnel expenses	23,364	25,315	46,678	44,765	84,682
Consulting expenses	8,875	6,290	16,578	13,841	28,873
Depreciation and amortization	159	130	325	282	635
Other expenses	7,176	9,318	13,330	14,024	27,961
Total	39,574	41,054	76,911	72,913	142,152

Not 5. Transactions with related parties

During the period, one board member has invoiced TSEK 670 (1,197) on market terms, for performed consulting services linked to the company's operational activities.

The services for 2024 are performed by Sorin Brull. For 2023, TSEK 632 of the services were performed by Sorin Brull and TSEK 565 by former board member, Jenny Freeman, who left her position as board member in November 2023.

Not 6. Earnings per share

SEK	Q2		Jan-Jun		Full-year
	2024	2023	2024	2023	2023
Basic earnings per share	-0.28	-0.42	-0.51	-0.84	-1.45
Diluted earnings per share	-0.28	-0.42	-0.51	-0.84	-1.45
Performance measure used in the calculation of earnings per share					
Results attributable to the parent company's shareholders are used	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period	Profit (-loss) for the period
Result attributable to the parent company's shareholders, SEK thousand	-33,411	-34,364	-61,340	-65,167	-134,149
No.					
Weighted average no. of ordinary shares for calculating basic earnings per share	119,705,523	82,566,660	119,705,523	77,634,509	92,269,497
Stock options					
Weighted average no. of ordinary shares and potential shares used as denominator for calculating diluted earnings per share	119,705,523	82,566,660	119,705,523	77,634,509	92,269,497

Earnings per share after dilution are not reported as it gives better earnings per share because the period's earnings are negative. In the rights issue carried out during Q1 2023 there is a bonus issue element, the effect is however insignificant as the subscription rights had a low value when the issue was not fully subscribed. Consequently, no recalculation has been made.

Not 7. Share capital development

Date	Event	Number of shares	Share capital (SEK)	Quotient value (SEK)
Januari 1, 2023	Opening balance	69,883,985	8,735,498	0.125
March 11, 2023	Right share issue	12,682,675	1,585,334	0.125
July 5, 2023	Set-off share issue RMI part 2	5,055,954	631,994	0.125
August 24, 2023	Directed shares issue	12,500,000	1,562,500	0.125
September 25, 2023	Directed shares issue	18,000,000	2,250,000	0.125
November 7, 2023	Set-off share issue RMI part 3	1,582,909	197,863	0.125
Total June 30, 2024		119,705,523	14,963,190	0.125



Not 8. Alternative performance measures

Senzime has defined alternative key figures as below. Calculations are published on the company's website www.senzime.com.

Performance measure	Definition	Motive for use
Gross margin excl. amortization	Gross profit (loss) excl. amortization of intangible assets divided by net sales	The group uses the alternative performance measure gross margin excluding amortization because it illustrates the impact of amortization of capitalized development expenditure on gross margin.
EBITA	Earnings before interest and taxes excluding amortization of intangible assets	The group uses the alternative performance measure EBITA because it illustrates the impact of amortization of capitalized development expenses on operating profit.
Equity/assets ratio	Closing equity in the period divided by closing total assets in the period	The group uses the alternative performance measure equity/assets ratio because it illustrates the portion of the total assets that consist of equity and has been included so investors will be able to assess the group's capital structure.
Items affecting comparability	Items of material value that do not have any clear relationship with ordinary activities and are of such nature that they cannot be expected to occur often. They may, for example, relate to acquisitions, major one-off orders, other unusual non-recurring revenue and expenses, capital gains/losses from divestments, restructuring expenses and impairment losses.	Enables improved understanding of the company's underlying operations.
Currency fluctuations	Adjusted for currency fluctuations on the net sales of operations excludes the effect of exchange rates by restating the net sales of operations for the relevant period by applying the rates of exchange used for the comparative period.	This performance measure is important for understanding the underlying progress of operations, and improves compatibility between periods

Not 9. Alternative performance measures

	Q2		Jan-Jun		Full-year	
	2024	2023	2024	2023	2023	
A	Net sales, TSEK	14,917	8,462	27,037	15,750	35,754
B	Gross profit excl. amortization, TSEK	9,435	5,927	17,233	10,918	24,947
B/A	Gross margin excl. amortization (%)	63.3%	70.0%	63.7%	69.3%	69.8%

	Q2		Jan-Jun		Full-year	
	2024	2023	2024	2023	2023	
Amounts in SEK thousands						
A	Earnings before interest and taxes	-34,720	-35,257	-64,055	-66,680	-137,360
B	Depreciation and amortization	5,481	5,056	10,904	10,019	20,567
A+B	EBITDA	-29,239	-30,201	-53,150	-56,661	-116,793

	Q2		Jan-Jun		Full-year	
	2024	2023	2024	2023	2023	
Amounts in SEK thousands						
A	Equity	319,693	283,912	319,693	283,912	375,477
B	Total assets	393,201	342,638	393,201	342,638	433,122
A/B	Equity/assets ratio, (%)	81.3%	82.9%	81.3%	82.9%	86.7%

Not 10. Employee stock option programs

Dilution from stock option programs

At the time this report is published, the group's four employee stock option programs comprise a total of 2,330,000 allocated options, which, if fully exercised, lead to a dilution of 2.23 percent. This is provided that all options are exercised.

During the period January-June 2024, no employee options have expired. A total of 214,000 employee options have so far expired and the remaining 2,116,000 employee options, if fully exercised, would represent a dilution of 2.05 percent. The corresponding figure excluding hedge options is 1.74%.

At the annual general meeting in May 2024, it was decided on another employee option program with a total of 1,200,000 options and allocation will take place during the third quarter of 2024.

About Senszime

Senzime is a Swedish medical technology company that develops, produces and markets patient monitoring systems.

Senzime's employees worldwide are committed to the vision of a world without anesthesia and breathing-related complications. The company markets an innovative portfolio of solutions, including TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular function and breathing during and after surgery.

The goal is to help eliminate care-related complications and radically reduce costs associated with surgical procedures and emergency treatments.

Senzime aims at a market valued at over SEK 40 billion per year and works with sales teams in the world's leading markets. The company's shares are listed on NASDAQ Stockholm's main market (SEZI) and cross traded on OTCQX (SNZZF).

More information is available at www.senzime.com.

Financial calendar 2024

Interim report Q3 2024	November 6
Year-End 2024 report	February 2025
Publication of Annual Report 2024	April 2025

Kontakt

Philip Siberg, CEO
Tel. +46 (0) 707 90 67 34
e-post: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Tel. +46 (0) 763 06 60 11
e-post: slavoljub.grujicic@senzime.com

Adress

Senzime AB
Verkstadsgatan 8
753 23 Uppsala
www.senzime.com